N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands

Journal of Medicinal Chemistry

Volumn 48, Issue 5, 2005, Pages 1421-1427

  Guerrini, Remo ^a   Caló, Girolamo ^a,c   Lambert, David G ^b   Carrá, Giacomo ^a   Arduin, Marika ^a   Barnes, Tim A ^b   McDonald, John ^b   Rizzi, Daniela ^a   Trapella, Claudio ^a   Marzola, Erika ^a   Rowbotham, David J ^b   Regoli, Domenico ^a   Salvador, Severo ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b Pharmacology and Therapeutics Group   (United Kingdom)

^c Section of Pharmacology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYCLOOCTYLMETHYL 3 HYDROXYMETHYL 4 PIPERIDYL) 3 ETHYL 1,3 DIHYDRO 2H BENZIMIDAZOL 2 ONE; 8 (2,3,3A,4,5,6 HEXAHYDRO 1H PHENALEN 1 YL) 1 PHENYL 1,3,8 TRIAZASPIRO[4.5]DECAN 4 ONE; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); LIGAND; NOCICEPTIN; NOCICEPTIN RECEPTOR; NOCICEPTIN RECEPTOR AGONIST; NOCICEPTIN RECEPTOR ANTAGONIST; SULFUR 35; SYNTHETIC PEPTIDE; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BIOASSAY; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; CHO CELL; DRUG POTENCY; DRUG RECEPTOR BINDING; GUINEA PIG; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS;

ANIMALS; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; CRICETULUS; ELECTRIC STIMULATION; GUINEA PIGS; HUMANS; ILEUM; LIGANDS; MALE; MICE; OPIOID PEPTIDES; RADIOLIGAND ASSAY; RECEPTORS, OPIOID; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; VAS DEFERENS;

EID: 20144384382     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040106v     Document Type: Article

References (41)

1. Abbreviations follow the IUPAC-IUB Joint Commission on Biochemical Nomenclature. Nomenclature and symbolism for amino acids and peptides. Eur. J. Biochem. 1984, 138, 9-37.
2. Reinscheid, R. K.; Nothacker, H. P.; Bourson, A.; Ardati, A.; Henningsen, R. A.; Bunzow, J. R.; Grandy, D. K.; Langen, H.; Monsma, F. J., Jr.; Civelli, O. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 1995, 270, 792-794.
3. Meunier, J. C.; Mollereau, C.; Toll, L.; Suaudeau, C.; Moisand, C.; Alvinerie, P.; Butour, J. L.; Guillemot, J. C.; Ferrara, P.; Monserrat, B.; Mazarguil, H.; Vassart, G.; Parmentier, M.; Costentin, J. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 1995, 377, 532-535.
4. Cox, B. M.; Chavkin, C.; Christie, M. J.; Civelli, O.; Evans, C.; Hamon, M. D.; Hoellt, V.; Kieffer, B.; Kitchen, I.; McKnight, A. T.; Meunier, J. C.; Portoghese, P. S. Opioid receptors. The IUPHAR Compendium of Receptor Characterization and Classification, 2nd ed.; IUPHAR Media Ltd: London, 2000; pp 321-333.
5. Mogil, J. S.; Pasternak, G. W. The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. Pharmacol. Rev. 2001, 53, 381-415.
6. Calo, G.; Guerrini, R.; Rizzi, A.; Salvadori, S.; Regoli, D. Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br. J. Pharmacol. 2000, 129, 1261-1283.
7. Zaveri, N. Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: Research tools and potential therapeutic agents. Life Sci. 2003, 73, 663-678.
8. Jenck, F.; Wichmann, J.; Dautzenberg, F. M.; Moreau, J. L.; Ouagazzal, A. M.; Martin, J. R.; Lundstrom, K.; Cesura, A. M.; Poli, S. M.; Roever, S.; Kolczewski, S.; Adam, G.; Kilpatrick, G. A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: Anxiolytic profile in the rat. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 4938-4943.
9. Ozaki, S.; Kawamoto, H.; Itoh, Y.; Miyaji, M.; Azuma, T.; Ichikawa, D.; Nambu, H.; Iguchi, T.; Iwasawa, Y.; Ohta, H. In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist. Eur. J. Pharmacol. 2000, 402, 45-53.
10. Becker, J. A.; Wallace, A.; Garzon, A.; Ingallinella, P.; Bianchi, E.; Cortese, R.; Simonin, F.; Kieffer, B. L.; Pessi, A. Ligands for kappa-opioid and ORL1 receptors identified from a conformationally constrained peptide combinatorial library. J. Biol. Chem. 1999, 274, 27513-27522.
11. Dooley, C. T.; Spaeth, C. G.; Berzetei-Gurske, I. P.; Craymer, K.; Adapa, I. D.; Brandt, S. R.; Houghten, R. A.; Toll, L. Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1. J. Pharmacol. Exp. Ther. 1997, 283, 735-741.
12. Calo, G.; Rizzi, A.; Bogoni, G.; Neugebauer, V.; Salvadori, S.; Beani, L.; Regoli, D.; Bianchi, C. The mouse vas deferens: a pharmacological preparation sensitive to nociceptin. Eur. J. Pharmacol. 1998, 311, R3-R5.
13. Guerrini, R.; Calo, G.; Rizzi, A.; Bianchi, C.; Lazarus, L. H.; Salvadori, S.; Temussi, P. A.; Regoli, D. Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide. J. Med. Chem. 1897, 40, 1789-1793.
14. Guerrini, R.; Calo, G.; Rizzi, A.; Bigoni, R.; Bianchi, C.; Salvadori, S.; Regoli, D. A new selective antagonist of the nociceptin receptor. Br. J. Pharmacol. 1998, 123, 163-165.
15. Calo, G.; Rizzi, A.; Marzola, G.; Guerrini, R.; Salvadori, S.; Beani, L.; Regoli, D.; Bianchi, C. Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay. Br. J. Pharmacol. 1998, 125, 373-378.
16. 2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist. J. Med. Chem. 1998, 41, 3360-3366.
17. Calo, G.; Guerrini, R.; Bigoni, R.; Rizzi, A.; Marzola, G.; Okawa, H.; Bianchi, C.; Lambert, D. G.; Salvadori, S.; Regoli, D. Characterization of [Nphe(1)]nociceptin(1-13)NH(2), a new selective nociceptin receptor antagonist. Br. J. Pharmacol. 2000, 129, 1183-1193.
18. Guerrini, R.; Calo, G.; Bigoni, R.; Rizzi, A.; Varani, K.; Toth, G.; Gessi, S.; Hashiba, E.; Hashimoto, Y.; Lambert, D. G.; Borea, P. A.; Tomatis, R.; Salvadori, S.; Regoli, D. Further studies on nociceptin-related peptides: discovery of a new chemical template with antagonist activity on the nociceptin receptor. J. Med. Chem. 2000, 43, 2805-2813.
19. Guerrini, R.; Calo, G.; Bigoni, R.; Rizzi, D.; Rizzi, A.; Zucchini, M.; Varani, K.; Hashiba, E.; Lambert, D. G.; Toth, G.; Borea, P. A.; Salvadori, S.; Regoli, D. Structure-activity studies of the Phe(4) residue of nociceptin(1-13)-NH(2): identification of highly potent agonists of the nociceptin/orphanin FQ receptor. J. Med. Chem. 2001, 44, 3956-3964.
20. Bigoni, R.; Rizzi, D.; Rizzi, A.; Camarda, V.; Guerrini, R.; Lambert, D. G.; Hashiba, E.; Berger, H.; Salvadori, S.; Regoli, D.; Calo, G. Pharmacological characterisation of [(pX)Phe(4)]-nociceptin(1-13)amide analogues. 1. In vitro studies. Naunyn-Schmiedeberg's Arch. Pharmacol. 2002, 365, 442-449.
21. Rizzi, A.; Salis, B.; Ciccocioppo, R.; Marzola, G.; Bigoni, R.; Guerrini, R.; Massi, M.; Madeddu, P.; Salvadori, S.; Regoli, D.; Calo, G. Pharmacological characterisation of [(pX)Phe(4)]-nociceptin(1-13)amide analogues. 2. In vivo studies. Naunyn-Schmiedeberg's Arch. Pharmacol. 2002, 365, 450-456.
22. Okada, K.; Sujaku, T.; Chuman, Y.; Nakashima, R.; Nose, T.; Costa, T.; Yamada, Y.; Yokoyama, M.; Nagahisa, A.; Shimohigashi, Y. Highly potent nociceptin analog containing the Arg-Lys triple repeat. Biochem. Biophys. Res. Commun. 2000, 278, 493-498.
23. Bigoni, R.; Giuliani, S.; Calo, G.; Rizzi, A.; Guerrini, R.; Salvadori, S.; Regoli, D.; Maggi, C. A. Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies. Naunyn-Schmiedeberg's Arch. Pharmacol. 1999, 359, 160-167.
24. Topham, C. M.; Mouledous, L.; Poda, G.; Maigret, B.; Meunier, J. C. Molecular modelling of the ORL1 receptor and its complex with nociceptin. Protein Eng. 1898, 11, 1163-1179.
25. 2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor. J. Pharmacol. Exp. Ther., in press.
26. 2 in rat brain, rat vas deferens and CHO cells expressing recombinant human nociceptin receptors. Br. J. Pharmacol. 1999, 127, 123-130.
27. 2 is an agonist of the nociceptin (ORL1) receptor. Eur. J. Pharmacol. 1998, 349, R5-R6.
28. McDonald, J.; Barnes, T. A.; Okawa, H.; Williams, J.; Calo, G.; Rowbotham, D. J.; Lambert, D. G. Partial agonist behaviour depends upon the level of nociceptin/orphanin FQ receptor expression: studies using the ecdysone-inducible mammalian expression system. Br. J. Pharmacol. 2003, 140, 61-70.
29. 2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br. J. Pharmacol. 2002, 136, 303-311.
30. Mela, F.; Marti, M.; Ulazzi, L.; Vaccari, E.; Zucchini, S.; Trapella, C.; Salvadori, S.; Beani, L.; Bianchi, C.; Morari, M. Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex. Eur. J. Neurosci. 2004, 19, 1317-1324.
31. Chiou, L. C.; Liao, Y. Y.; Calo', G.; Guerrini, R. UFP-101 is a competitive antagonist of N/OFQ receptors mediating inwardly rectifying K+ channel activation in rat periaquedutal gray slices. Presented at the Meeting of the Federation of European Neurosciences Lisbon, Portugal, July 10-14, 2004.
32. Basso, M.; Naline, E.; Calo, G.; Guerrini, R.; Regoli, D.; Advenier, C. Effects of NOP ligands in the electrically stimulated human bronchus. Presented at the Meeting of La Nocicettina/Orfanina FQ Ed Il Suo Recettore, Camerino, Italy, September 15, 2003.
33. Trombella, S.; Vergura, R.; Guerrini, R.; Calo, G.; Spisani, S. Chemotactic effects of nociceptin/orphanin FQ on human monocytes are mediated by NOP receptor activation. Presented at the Meeting of La Nocicettina/Orfanina FQ Ed Il Suo Recettore, Camerino, Italy, September 15, 2003.
34. Rizzi, A.; Marzola, G.; Gavioli, E. C.; Guerrini, R.; Zucchini, S.; Kenigs, V. A.; Kapusta, D. R.; Salvadori, S.; Regoli, D.; Calo, G. Antinociceptive effects induced by spinal nociceptin/orphanin FQ administration are due to NOP receptor activation: phamacological and genetic evidences in mice. Presented at EPHAR, the Federation of European Pharmacological Societies, Porto, Portugal, 2004.
35. Redrobe, J. P.; Calo, G.; Regoli, D.; Quirion, R. Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test. Naunyn-Sehmiedeberg's Arch. Pharmacol. 2002, 365, 164-167.
36. Gavioli, E. C.; Marzola, G.; Guerrini, R.; Bertorelli, R.; Zucchini, S.; De Lima, T. C.; Rae, G. A.; Salvadori, S.; Regoli, D.; Calo, G. Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test. Eur. J. Neurosci. 2003, 17, 1987-1990.
37. Gavioli, E. C.; Vaughan, C. W.; Marzola, G.; Guerrini, R.; Mitchell, V. A.; Zucchini, S.; De Lima, T. C.; Rae, G. A.; Salvadori, S.; Regoli, D.; Calo, G. Antidepressant-like effects of the nociceptin/orphanin FQ receptor antagonist UFP-101: new evidences in rats and mice. Naunyn-Schmiedeberg's Arch. Pharmacol. 2004, 369, 547-553.
38. Hashiba, E.; Hirota, K.; Kudo, T.; Calo', G.; Guerrini, R.; Matsuki, A. Effects of nociceptin/orphanin FQ receptor ligands on blood pressure, heart rate and plasma catecholamine concentrations in guinea pigs. Naunyn-Schmiedeberg's Arch. Pharmacol. 2003, 367, 342-347.
39. Lowry, O. H.; Nira, J.; Rosenbrough, A.; Farr, L.; Randall, R. J. Protein measurements with the Folin phenol reagent. J. Biol. Chem. 1951, 193, 265-275.
40. Neubig, R. R.; Spedding, M.; Kenakin, T.; Christopoulos, A. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol. Rev. 2003, 55, 597-606.
41. Hashiba, E.; Harrison, C.; Galo, G.; Guerrini, R.; Rowbotham, D. J.; Smith, G.; Lambert, D. G. Characterisation and comparison of novel ligands for the nociceptin/orphanin FQ receptor. Naunyn-Schmiedeberg's Arch. Pharmacol. 2001, 363, 28-33.